Arecor is a revenue-generating clinical-stage drug developer. Its proprietary Arestat formulation platforms are the basis of an in-house and partnered pipeline of enhanced products with lower development risks and less onerous regulatory approvals.
Momentum continues to build across Arecor’s pipeline and 2023 should see the first Arestat-based product, AT220, approved and entering a multi-billion market. Partner Hikma has confirmed it will progress AT307 through to commercialisation, with several milestones expected over the coming 18 months. Two new formulation collaborations have been signed, and one has been extended. The diabetes franchise remains in the spotlight with changing US insulin market dynamics. Insulins AT278 (ultra-concentrated, ultra-rapid) and AT247 (ultra-rapid, pump-optimised) have highly promising profiles that should be ideally placed for emerging diabetes needs. AT278 is in a second Phase I trial, with key data expected in Q423. Arecor’s formulation expertise underpins both the in-house clinical pipeline and the partnered Specialty Hospital Products programmes. Our updated valuation is £176m, or 575p per share.
| Symbol | Primary exchanges |
| AREC | AIM London |